GlassScriptPhysician profile
George A Ponce
NPI 1174554935
$14,187.75
in general payments reported to CMS, 2019-2025
43 companies · $3,048 in 2025
The $3,048 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $831 · 2021: $1,290 · 2022: $1,178 · 2023: $1,136 · 2024: $5,878 · 2025: $3,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,160 · Travel and Lodging: $2,066 · Consulting Fee: $1,825 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,159.59 |
| Travel and Lodging | $2,065.65 |
| Consulting Fee | $1,825.00 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,946.34 | 2021-2025 | Micra, Corevalve Evolut R, Onyx Frontier |
| Inari Medical, INC. | $2,185.58 | 2022-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Bayer Healthcare Pharmaceuticals INC. | $673.64 | 2021-2025 | |
| Amarin Pharma, INC. | $663.82 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $590.29 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $555.09 | 2022-2025 | Winrevair, Verquvo, Capvaxive |
| Boston Scientific Corporation | $543.97 | 2021-2025 | Ranger, General - Therapies, Accolade Sr |
| Abiomed | $487.59 | 2020-2025 | Impella |
| Pfizer INC. | $417.58 | 2021-2025 | |
| Stryker Corporation | $397.33 | 2025 | Flowtriever, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.92 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $347.66 | 2022-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $339.50 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $305.59 | 2019-2023 | Xarelto |
| Cardiovascular Systems INC. | $294.68 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $233.02 | 2023-2025 | Tyvaso, Tyvaso |
| Novo Nordisk INC | $193.63 | 2021-2025 | Ozempic, Rybelsus |
| Actelion Pharmaceuticals US, INC. | $170.27 | 2019-2022 | |
| Biotronik INC. | $156.46 | 2019-2024 | Renamic Neo |
| Cathworks, INC. | $141.47 | 2019-2022 | |
| Medtronic Vascular, INC. | $140.88 | 2019-2020 | |
| Penumbra, INC. | $133.39 | 2023 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $133.20 | 2019-2025 | Farxiga |
| Amgen INC. | $115.13 | 2024-2025 | Repatha, Repatha |
| Abbott Laboratories | $106.61 | 2023-2025 | Diamondback Coronary, Gallant, Jot Dx |
| Lilly USA, LLC | $66.67 | 2021-2023 | Jardiance, Emgality |
| Heartflow, INC. | $63.79 | 2025 | |
| Kestra Medical Technology Services, INC. | $57.27 | 2022-2024 | Assure Wcd |
| Scpharmaceuticals INC. | $52.73 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $39.39 | 2024 | Arcalyst |
| Strongbridge US INC. | $38.68 | 2019 | |
| Baxter Healthcare | $38.48 | 2022 | |
| Ionis Pharmaceuticals, INC. | $28.33 | 2025 | Tryngolza |
| Bard Peripheral Vascular, INC. | $27.83 | 2025 | Lifestent Solo Vascular Stent |
| Kiniksa Pharmaceuticals, LTD. | $20.24 | 2022 | |
| Astellas Pharma US INC | $20.23 | 2019 | |
| Shockwave Medical, INC | $18.28 | 2021 | |
| Convatec INC. | $16.18 | 2023 | |
| Kyowa Kirin, INC. | $15.85 | 2023 | |
| Ge Healthcare | $15.65 | 2023 | |
| Philips North America LLC | $13.20 | 2019 | |
| Smith+Nephew, INC. | $13.18 | 2019 | |
| Teleflex LLC | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Ponce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.